Helixmith Obtains Domestic Patent for ADHD Treatment Substance ‘HX106’

[Asia Economy Reporter Hyungsoo Park] Helixmith announced on the 3rd that it has obtained a domestic patent for ‘HX106,’ a candidate substance for the treatment and improvement of Attention Deficit Hyperactivity Disorder (ADHD).

HX106 inhibits the overactivation of glutamate receptors, which are known to cause ADHD. When combined with the representative treatment methylphenidate, it showed effects in improving attention deficits and hyperactivity in children with ADHD.

HX106 is a plant-based complex extract developed by Helixmith’s natural products research team. It demonstrated efficacy in improving working memory and was approved as a individually recognized ingredient by the Ministry of Food and Drug Safety in 2015. It also received safety recognition through NDI (New Dietary Ingredients) certification from the U.S. FDA.

In Korea, three treatments are currently used: methylphenidate, atomoxetine, and clonidine. Various side effects such as insomnia, loss of appetite, cardiovascular problems, and delayed growth in children have been reported.

Yoo Seung-shin, CEO of Helixmith, said, "Current drugs used for ADHD treatment have limited effectiveness and sometimes cause side effects," adding, "HX106 is composed of plant materials whose safety has been proven in the U.S., so expectations are high."

This content was produced with the assistance of AI translation services.